New Anti-Alzheimer Investigational Drug Shows Major Treatment Promise

Ready for prime time by 2012? That’s what some researchers are saying about the anti-Alzheimer drug in the second stage of its development. The investigational drug is the first to attack the chronic degenerative disease at its core: the formation of proteinaceous neurotoxins (tau proteins) which are pathognomonic for the disorder. Early data show absolutely no decline in patients’ cognitive functioning over six months while on the drug — something not possible by the current crop of FDA approved agents for dementia (as cognitive decline is slowed, but not absolutely halted). | LINK